Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
May 06, 2024
MEL practitioners—and knowledge producers more generally—should adopt an approach that is attuned to a realistic model of the stages of the policy process and be ready to seize windows of opportunity to apply evidence. This may require navigating competing demands, recognizing tradeoffs, and making ...
Blog Post
April 05, 2024
As the Center for Global Development’s inaugural Evidence in Policy Fellow, I just finished an extended engagement to help increase data and evidence use in the State Department’s Office of Foreign Assistance. While at State, I spent much of my time leading and participating in the work of the inter...
Blog Post
March 29, 2024
The US foreign assistance data for FY 2022 is nearly complete, except for some missing Department of Defense, Homeland Security, and Transportation data, and the data reveals some interesting trends. First, FY 2022 did not break the historical record of total obligations, but it came closer than any...
Blog Post
March 27, 2024
Today marks a significant milestone as the Bill & Melinda Gates Foundation (BMGF) announces a new Open Access policy, representing a departure from traditional practices. This policy will cease support for individual article publishing fees, known as APCs, and mandate the use of preprints while advo...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...